Objective: Indirectly compare the efficacy and safety of ertugliflozin (ertu) from the VERTIS MET and FACTORIAL trials to other SGLT2i as an add-on to MET.

Methods: Pubmed, EMBASE and Cochrane databases were searched through to end 2016 for RCTs of 24-26 weeks duration in T2DM patients with uncontrolled A1C on MET. Comparators to ertu 5mg and 15mg were low and high doses of SGLT2i licensed in Europe and USA: canagliflozin (cana), dapagliflozin (dapa) and empagliflozin (empa). Included outcomes vs. placebo at 24-26 weeks were change in A1C, weight, systolic blood pressure (SBP), A1C <7% and safety outcomes (urinary tract infections [UTIs], genital mycotic infections [GMIs], hypoglycemic events and patients with ≥1 adverse event [AE]). Evidence synthesis used both fixed effect (FE) and random effects (RE) Bayesian NMA, with model selection informed by guidelines. Credible intervals (CrI), analogous to 95% confidence intervals, were used to determine significance.

Results: The NMA included 7 RCTs. Ertu was significantly more effective in reducing A1C than dapa doses (ertu 5mg vs. dapa 5mg mean difference (MD): -0.22%, CrI -0.42, -0.02; ertu 15mg vs. dapa 10mg MD:-0.26%, CrI -0.46, -0.06) and ertu 15mg was superior to empa 25mg (MD: -0.23%, CrI -0.44, -0.03). There were no further significant differences between ertu and other SGLT2i for change in A1C, SBP, weight, A1C <7%, UTIs or ≥1 AEs. Limited number of hypoglycemic and GMI events in placebo comparators resulted in non-convergence for these networks. The impact of heterogeneity was tested, but potential confounding due to differences in factors such as study design and patient population may remain.

Conclusions: Although reliant upon indirect comparison rather than head to head RCTs, ertu 5 and 15mg were superior to dapa 5 and 10mg, respectively, and ertu 15mg was superior to empa 25mg. Across remaining outcomes, both ertu doses added to MET were comparable to other SGLT2i.

Disclosure

A. McNeill: Employee; Self; Merck & Co., Inc.. Stock/Shareholder; Self; Merck & Co., Inc. G.M. Davies: Employee; Self; Merck & Co., Inc. E. Kruger: Employee; Self; QuintilesIMS. T. Reason: None. F. Ejzykowicz: Employee; Self; Merck Sharp & Dohme Corp. H. Hannachi: Employee; Self; Merck & Co., Inc. N.B. Cater: Employee; Self; Peter Sheehan Diabetes Care Foundation, Inc. E. McLeod: Employee; Self; Pfizer Inc..

© 2018 by the American Diabetes Association.
2018
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.